Enovis Corporation (NYSE:ENOV) Shares Purchased by Homestead Advisers Corp

Homestead Advisers Corp boosted its holdings in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 15.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,476 shares of the company's stock after buying an additional 10,300 shares during the period. Homestead Advisers Corp owned approximately 0.14% of Enovis worth $2,960,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its holdings in Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after acquiring an additional 536 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in Enovis during the fourth quarter worth approximately $29,000. Quadrant Capital Group LLC boosted its position in Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after purchasing an additional 239 shares in the last quarter. Quarry LP lifted its position in shares of Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 749 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Enovis by 144.8% in the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after acquiring an additional 692 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Trading Down 0.4%

ENOV stock traded down $0.12 during midday trading on Friday, hitting $27.04. 352,168 shares of the company's stock were exchanged, compared to its average volume of 1,186,134. The business has a 50-day simple moving average of $31.86 and a two-hundred day simple moving average of $36.73. The company has a current ratio of 2.55, a quick ratio of 1.32 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $1.54 billion, a PE ratio of -1.94 and a beta of 1.70. Enovis Corporation has a 1-year low of $25.93 and a 1-year high of $49.83.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The company had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. During the same quarter last year, the firm earned $0.50 earnings per share. The firm's quarterly revenue was up 8.2% compared to the same quarter last year. On average, sell-side analysts predict that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ENOV. Canaccord Genuity Group decreased their target price on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Evercore ISI cut their target price on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Needham & Company LLC cut their target price on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $55.60.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.